替吉奥阿帕替尼治疗晚期难治性卵巢癌的疗效对比及药物对HE4 CA125及CA199的影响

Comparison of Efficacy of Teguio and Apatinib in the Treatment of Advanced Refractory Ovarian Cancer and the Effect of Drugs on HE4 CA125 and CA199

目的:对晚期难治性卵巢癌(OC)患者分别使用阿帕替尼、替吉奥治疗,观察比较两组的临床效果,并探讨以上药物治疗对人附睾分泌蛋白4(HE4)、糖类抗原125(CA125)、糖类抗原199(CA199)的影响。方法:回顾性分析2018年4月至2019年9月本院收治的88例难治性OC患者(TNMⅢ~Ⅳ期),按治疗方法不同将患者分为观察组44例(采用甲磺酸阿帕替尼治疗)及对照组44例(采用替吉奥方案治疗),对比两组患者用药前后的HE4、CA125、CA199变化,评估治疗后两组的总有效率、疾病控制率以及不良反应发生率。结果:观察组治疗后总有效率50.00%,显著高于对照组的27.27%(P<0.05);与对照组治疗后比,观察组血清HE4、CA125、CA199水平均有明显降低(P均<0.05);对照组治疗后非血液学不良反应率为75.00%、血液学不良反应率为77.27%,较观察组的52.27%及36.36%均有明显升高(P均<0.05)。结论:对晚期难治性OC患者采用阿帕替尼治疗的疗效理想,不良反应少,疾病控制率佳,考虑原因可能与阿帕替尼可明显抑制HE4、CA125、CA199水平有关,具有临床推广价值。

Objective:To observe the clinical efficacy of apatinib and tigio for patients with advanced refractory ovarian cancer(OC),and to explore the effect of the above drugs on human epididymal secretory protein 4(HE4),carbohydrate antigen 125(CA125)and carbohydrate antigen 199(CA199).Methods:Retrospective analysis was conducted of 88 patients with refractory OC from April 2018 to September 2019(TNMⅢ-Ⅳ),who were divided into observation group(treated with apatinib mesylate)and control group(treated with tigio),with 44 cases in each.The changes of HE4,CA125 and CA199 were compared between the two groups.The total effective rates,disease control rates and adverse reactions were compared between the two groups.Results:After treatment,the total effective rate of observation group was 50.00%,which was significantly higher than that of control group(P<0.05).The serum HE4,CA125,CA199 levels in the observation group decreased significantly compared with those in the control group(all P<0.05).The rates of non-hematological and hematological adverse reactions were 75.00%and 77.27%in the control group after treatment;there was a significant increase in 52.27%and 36.36%of the observation group(all P<0.05).Conclusion:Apatinib treatment for advanced refractory OC patients is ideal,with less adverse reactions and better disease control.It is considered to be related to the obvious inhibition of apatinib HE4、CA125、CA199 level,which has clinical value.